Search Intelligence

“Like most AI pharma pacts, the massive $1.5B headline figure obscures the reality that AstraZeneca is only risking $40M in actual cash upfront, effectively buying a relatively cheap call option on insitro's machine learning models finding viable targets.”

“Billions spent hyping a biological mechanism only to watch the clinical trial completely collapse on first contact with reality.”